Increasing the accuracy for endoscopic detection of early Barrett neoplasia, by adding probe-based confocal laser endomicroscopy to endoscopic tri-modal imaging: A feasibility study on Endoscopic Quad-Modal Imaging (EQMI)
- Conditions
- (1) Barrett esophagus(2) early esophageal neoplasia1001799010017991
- Registration Number
- NL-OMON33330
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 15
- Age > 18 years;
- BO with a minimal circumferential length of 2 cm;
- BO without dysplasia or with LGIN (i.e. surveillance patients) or patients with BO referred for endoscopic work-up of HGIN/early cancer;
- Signed informed consent.
- Prior history of surgical or endoscopic treatment of esophageal neoplasia;
- Presence of erosive oesophagitis (Los Angeles classification *B);
- Inability to obtain biopsies or to perform an endoscopic resection (e.g. due to anticoagulation, coagulation disorders, varices);
- Contraindication for fluorescein administration (e.g. allergy, pregnancy, beta-blocker use);
- Unable to provide signed informed consent.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Study Phase 1:<br /><br>(1) Correlation of the real-time NBI evaluation with histological outcome;<br /><br>(2) Correlation of the real-time pCLE evaluation with histological outcome;<br /><br>(3) Reduction of the false positive rate of WLE and AFI with NBI;<br /><br>(4) Reduction of the false positive rate of WLE and AFI with pCLE.<br /><br><br /><br>Study Phase 2:<br /><br>(1) Number of endoscopic resection specimens containing early neoplasia (i.e.<br /><br>HGIN/EC) upon histological evaluation;<br /><br>(2) Number of endoscopic resection specimens without early neoplasia upon<br /><br>histological evaluation;<br /><br>(3) Number of biopsies from areas graded as negative or indefinite upon<br /><br>endoscopy, containing early neoplasia upon histological evaluation.</p><br>
- Secondary Outcome Measures
Name Time Method <p>--</p><br>